nifedipine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
calcium channel blockers, nifedipine derivatives 1922 21829-25-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • BAY A1040
  • nifedipine
  • nedipin
  • fedipin
A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
  • Molecular weight: 346.34
  • Formula: C17H18N2O6
  • CLOGP: 3.12
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 1
  • TPSA: 110.45
  • ALOGS: -4.29
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg O
30 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.01 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.01 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.71 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 50 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.79 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 7.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.04 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.90 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 31, 1981 FDA PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Premature delivery 352.47 9.61 249 51787 21820 46612206
Exposure during pregnancy 219.26 9.61 415 51621 107797 46526229
Premature baby 208.37 9.61 168 51868 17944 46616082
Low birth weight baby 140.38 9.61 83 51953 5351 46628675
Pre-eclampsia 134.10 9.61 93 51943 7901 46626125
Maternal exposure during pregnancy 124.15 9.61 320 51716 102229 46531797
Foetal exposure during pregnancy 111.82 9.61 154 51882 30593 46603433
Hypertension 104.88 9.61 465 51571 195891 46438135
Blood pressure inadequately controlled 100.15 9.61 62 51974 4344 46629682
Premature labour 84.27 9.61 82 51954 11217 46622809
Caesarean section 66.21 9.61 87 51949 16516 46617510
Hypotension 61.70 9.61 457 51579 232132 46401894
Oedema peripheral 57.63 9.61 339 51697 159367 46474659
Blood pressure increased 55.17 9.61 283 51753 126383 46507643
Renal impairment 53.12 9.61 193 51843 74179 46559847
Foetal growth restriction 51.50 9.61 49 51987 6518 46627508
Blood pressure diastolic abnormal 49.43 9.61 47 51989 6247 46627779
Blood pressure systolic abnormal 48.75 9.61 44 51992 5473 46628553
Alopecia 48.56 9.61 66 51970 162348 46471678
Drug ineffective 44.10 9.61 514 51522 677324 45956702
Drug abuse 43.16 9.61 9 52027 63399 46570627
Scleroderma 43.05 9.61 38 51998 4591 46629435
Intestinal angioedema 42.26 9.61 18 52018 571 46633455
Dyspnoea exertional 41.55 9.61 137 51899 50152 46583874
Cardiac failure congestive 39.93 9.61 205 51831 91545 46542481
Heart rate decreased 39.36 9.61 100 51936 31623 46602403
Treatment failure 39.13 9.61 28 52008 93059 46540967
Drug dispensed to wrong patient 38.35 9.61 13 52023 216 46633810
Proteinuria 37.88 9.61 67 51969 16486 46617540
Hypergammaglobulinaemia 35.78 9.61 15 52021 457 46633569
Rectal prolapse 35.45 9.61 22 52014 1548 46632478
Neutropenia 35.41 9.61 66 51970 143138 46490888
Primary hyperaldosteronism 35.34 9.61 9 52027 50 46633976
Polyhydramnios 35.28 9.61 24 52012 1975 46632051
Rheumatoid arthritis 35.21 9.61 143 51893 240072 46393954
Cerebral infarction 34.74 9.61 79 51957 23287 46610739
Pemphigus 33.92 9.61 5 52031 45269 46588757
Psoriasis 33.89 9.61 23 52013 78581 46555445
Eclampsia 33.68 9.61 13 52023 318 46633708
Injection site erythema 33.14 9.61 21 52015 74406 46559620
Oligohydramnios 32.30 9.61 35 52001 5430 46628596
Bladder prolapse 31.68 9.61 22 52014 1872 46632154
Acute pulmonary oedema 30.92 9.61 41 51995 7850 46626176
Transfusion 30.85 9.61 54 51982 13177 46620849
Pulmonary oedema 30.25 9.61 125 51911 50980 46583046
Blood aldosterone increased 29.74 9.61 10 52026 162 46633864
Foetal death 29.11 9.61 42 51994 8701 46625325
CD30 expression 28.80 9.61 7 52029 31 46633995
Premature separation of placenta 28.74 9.61 20 52016 1708 46632318
Porphyria acute 28.49 9.61 12 52024 370 46633656
Blood pressure systolic increased 27.05 9.61 82 51954 28705 46605321
Blood creatinine increased 26.12 9.61 160 51876 76243 46557783
Neonatal respiratory distress syndrome 26.00 9.61 22 52014 2511 46631515
BRASH syndrome 25.84 9.61 8 52028 98 46633928
Renal artery stenosis 25.84 9.61 19 52017 1769 46632257
Tubulointerstitial nephritis 25.40 9.61 53 51983 14735 46619291
Bradycardia 25.35 9.61 143 51893 66155 46567871
Product residue present 24.96 9.61 26 52010 3856 46630170
Angina unstable 24.76 9.61 36 52000 7512 46626514
Dialysis 24.52 9.61 42 51994 10074 46623952
Foetal exposure timing unspecified 24.51 9.61 9 52027 191 46633835
Infrequent bowel movements 23.69 9.61 15 52021 1093 46632933
Dyspnoea 23.62 9.61 746 51290 514802 46119224
Injection site reaction 23.45 9.61 12 52024 47837 46586189
Aplastic anaemia 23.29 9.61 34 52002 7119 46626907
Oedema 23.27 9.61 141 51895 66930 46567096
Contraindicated product administered 22.38 9.61 34 52002 79913 46554113
Electrocardiogram PR prolongation 22.26 9.61 12 52024 647 46633379
Injection site inflammation 22.17 9.61 22 52014 3080 46630946
Finger amputation 21.82 9.61 11 52025 516 46633510
Thermal burn 21.72 9.61 27 52009 4850 46629176
Maternal condition affecting foetus 21.06 9.61 8 52028 187 46633839
HELLP syndrome 20.97 9.61 13 52023 913 46633113
Rash 20.55 9.61 277 51759 356235 46277791
Endometritis 20.30 9.61 13 52023 966 46633060
Hypertensive crisis 20.20 9.61 46 51990 13569 46620457
Pulmonary hypertension 19.72 9.61 86 51950 35907 46598119
Blood pressure fluctuation 19.23 9.61 76 51960 30372 46603654
Renal hypoplasia 19.17 9.61 5 52031 31 46633995
Glossodynia 19.10 9.61 13 52023 44360 46589666
Bradycardia foetal 19.02 9.61 9 52027 367 46633659
Cardiac failure 18.86 9.61 153 51883 79795 46554231
Aortic dissection 18.80 9.61 15 52021 1577 46632449
Multiple sclerosis relapse 18.59 9.61 12 52024 42113 46591913
Wrong technique in product usage process 18.48 9.61 20 52016 54402 46579624
Patent ductus arteriosus 18.20 9.61 22 52014 3840 46630186
Vitamin D decreased 18.12 9.61 32 52004 7861 46626165
Fluid overload 18.10 9.61 69 51967 27116 46606910
Product complaint 18.08 9.61 41 51995 12060 46621966
Oral herpes 18.00 9.61 55 51981 19335 46614691
Sinusitis 17.90 9.61 79 51957 129689 46504337
Barotrauma 17.66 9.61 7 52029 184 46633842
Foetal exposure during delivery 17.64 9.61 5 52031 44 46633982
Renin decreased 17.57 9.61 6 52030 102 46633924
Peripheral vascular disorder 17.45 9.61 27 52009 5950 46628076
Febrile neutropenia 17.44 9.61 51 51985 94576 46539450
Blood urea increased 17.42 9.61 65 51971 25287 46608739
Vascular resistance systemic increased 17.40 9.61 3 52033 0 46634026
Tocolysis 17.40 9.61 3 52033 0 46634026
Foetal distress syndrome 17.40 9.61 13 52023 1240 46632786
Phaeochromocytoma 17.16 9.61 9 52027 459 46633567
Therapeutic product effect decreased 17.13 9.61 42 51994 82559 46551467
Uraemic encephalopathy 17.05 9.61 7 52029 202 46633824
Injection site pain 16.82 9.61 62 51974 107090 46526936
Suicidal ideation 16.74 9.61 23 52013 56359 46577667
Urticaria 16.73 9.61 71 51965 117821 46516205
Injection site pruritus 16.64 9.61 12 52024 39731 46594295
Peripartum cardiomyopathy 16.62 9.61 6 52030 121 46633905
Hypertensive emergency 16.50 9.61 14 52022 1604 46632422
Diabetic nephropathy 16.39 9.61 13 52023 1355 46632671
Nephrogenic systemic fibrosis 16.00 9.61 23 52013 4749 46629277
Cerebrovascular accident 15.69 9.61 177 51859 100862 46533164
Cognitive disorder 15.62 9.61 11 52025 36872 46597154
Product substitution error 15.45 9.61 4 52032 24 46634002
Preterm premature rupture of membranes 15.06 9.61 11 52025 1014 46633012
Fluid retention 15.05 9.61 103 51933 50943 46583083
Dermatophytosis of nail 14.98 9.61 5 52031 79 46633947
Laboratory test interference 14.91 9.61 9 52027 602 46633424
Ileal ulcer 14.71 9.61 8 52028 439 46633587
Pseudolymphoma 14.69 9.61 9 52027 619 46633407
Arthropathy 14.65 9.61 47 51989 84653 46549373
Malignant hypertension 14.64 9.61 11 52025 1058 46632968
Hypovolaemic shock 14.56 9.61 23 52013 5160 46628866
Pulmonary embolism 14.44 9.61 67 51969 108518 46525508
Joint range of motion decreased 14.13 9.61 43 51993 15081 46618945
Skin induration 14.11 9.61 17 52019 2957 46631069
Joint swelling 14.02 9.61 118 51918 165955 46468071
Blood pressure decreased 13.81 9.61 110 51926 57049 46576977
Pain 13.73 9.61 416 51620 476532 46157494
Rheumatoid factor positive 13.72 9.61 3 52033 20458 46613568
Infusion related reaction 13.72 9.61 62 51974 101146 46532880
Thrombocytopenia 13.56 9.61 84 51952 126497 46507529
Cortisol increased 13.47 9.61 7 52029 350 46633676
Migraine 13.45 9.61 37 51999 69989 46564037
Umbilical cord vascular disorder 13.41 9.61 5 52031 111 46633915
Fatigue 13.38 9.61 549 51487 608148 46025878
Adverse drug reaction 13.27 9.61 18 52018 44344 46589682
Stillbirth 13.24 9.61 25 52011 6466 46627560
Haemoperitoneum 13.13 9.61 15 52021 2467 46631559
Blood corticotrophin decreased 13.08 9.61 6 52030 228 46633798
Knee arthroplasty 13.07 9.61 5 52031 23660 46610366
Antibody test positive 13.03 9.61 14 52022 2151 46631875
Human chorionic gonadotropin positive 13.00 9.61 4 52032 48 46633978
Hypertensive cardiomyopathy 12.98 9.61 6 52030 232 46633794
Respiratory distress 12.97 9.61 70 51966 31846 46602180
Blood pressure diastolic decreased 12.90 9.61 40 51996 14171 46619855
Microvillous inclusion disease 12.79 9.61 3 52033 11 46634015
Shock 12.58 9.61 53 51983 21792 46612234
Neonatal hyponatraemia 12.57 9.61 4 52032 54 46633972
Left ventricular hypertrophy 12.55 9.61 21 52015 4942 46629084
Atrial septal defect 12.44 9.61 24 52012 6308 46627718
Pain in jaw 12.26 9.61 79 51957 38293 46595733
Cervical incompetence 12.25 9.61 8 52028 615 46633411
Renal failure 12.19 9.61 186 51850 113408 46520618
Aortic valve incompetence 12.18 9.61 23 52013 5947 46628079
Myocardial infarction 12.18 9.61 164 51872 97364 46536662
Cardiomegaly 12.16 9.61 45 51991 17437 46616589
Hypersensitivity 12.16 9.61 108 51928 150213 46483813
Therapy partial responder 12.09 9.61 20 52016 4662 46629364
Feeling cold 11.97 9.61 47 51989 18724 46615302
Intentional overdose 11.97 9.61 35 52001 64909 46569117
Device expulsion 11.95 9.61 8 52028 27534 46606492
Skin hypertrophy 11.94 9.61 16 52020 3095 46630931
Respiratory tract inflammation 11.88 9.61 7 52029 448 46633578
Palpitations 11.82 9.61 160 51876 95099 46538927
Chronic kidney disease 11.77 9.61 82 51954 40789 46593237
Urine output decreased 11.76 9.61 33 52003 11064 46622962
Intestinal pseudo-obstruction 11.75 9.61 8 52028 659 46633367
Spinal cord infarction 11.73 9.61 6 52030 290 46633736
Shunt stenosis 11.70 9.61 6 52030 292 46633734
Glomerulonephritis membranoproliferative 11.53 9.61 5 52031 166 46633860
Small for dates baby 11.43 9.61 17 52019 3620 46630406
Joint contracture 11.38 9.61 11 52025 1491 46632535
Gestational hypertension 11.36 9.61 13 52023 2142 46631884
Blood lactate dehydrogenase increased 11.24 9.61 49 51987 20451 46613575
Neuromuscular blockade 11.22 9.61 6 52030 318 46633708
Angina pectoris 11.07 9.61 59 51977 26716 46607310
Ductus arteriosus premature closure 10.95 9.61 6 52030 334 46633692
Renal atrophy 10.92 9.61 10 52026 1267 46632759
Hyperkalaemia 10.87 9.61 95 51941 50614 46583412
Ventricular hypertrophy 10.82 9.61 17 52019 3797 46630229
Right atrial enlargement 10.80 9.61 4 52032 87 46633939
Accidental exposure to product 10.76 9.61 5 52031 21076 46612950
Somnolence 10.75 9.61 117 51919 156404 46477622
Medication error 10.72 9.61 65 51971 30846 46603180
Hepatic enzyme increased 10.56 9.61 51 51985 81736 46552290
Skin tightness 10.56 9.61 17 52019 3876 46630150
Hepatic rupture 10.52 9.61 3 52033 27 46633999
Depressed mood 10.50 9.61 13 52023 33306 46600720
Injection site swelling 10.48 9.61 18 52018 40309 46593717
Ischaemic skin ulcer 10.43 9.61 3 52033 28 46633998
Atrioventricular block first degree 10.42 9.61 22 52014 6164 46627862
Hyperplasia adrenal 10.33 9.61 3 52033 29 46633997
Discomfort 10.26 9.61 23 52013 46647 46587379
Live birth 10.25 9.61 30 52006 10300 46623726
Premature rupture of membranes 10.24 9.61 18 52018 4405 46629621
Carotid artery disease 10.24 9.61 11 52025 1690 46632336
Hypoperfusion 10.16 9.61 10 52026 1387 46632639
Chills 10.14 9.61 64 51972 95968 46538058
Large intestine benign neoplasm 10.13 9.61 4 52032 104 46633922
Metabolic acidosis 10.12 9.61 76 51960 38704 46595322
Drug titration error 10.09 9.61 7 52029 595 46633431
Foetal heart rate decreased 10.06 9.61 4 52032 106 46633920
Nausea 9.94 9.61 647 51389 686807 45947219
Jaundice neonatal 9.91 9.61 8 52028 855 46633171
Sodium retention 9.90 9.61 3 52033 34 46633992
Systemic scleroderma 9.88 9.61 8 52028 858 46633168
Eosinophilic colitis 9.82 9.61 4 52032 113 46633913
Anaemia neonatal 9.77 9.61 5 52031 242 46633784
Congenital hypothyroidism 9.77 9.61 5 52031 242 46633784
Paranasal sinus inflammation 9.73 9.61 5 52031 244 46633782
Multiple sclerosis 9.72 9.61 8 52028 24783 46609243
Amniotic cavity infection 9.64 9.61 9 52027 1169 46632857

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Premature baby 145.35 10.36 136 35612 16555 29900175
Foetal exposure during pregnancy 109.45 10.36 174 35574 36697 29880033
Low birth weight baby 93.75 10.36 69 35679 6007 29910723
Bradycardia 73.91 10.36 208 35540 65318 29851412
Solar lentigo 66.26 10.36 22 35726 318 29916412
Photodermatosis 64.72 10.36 23 35725 412 29916318
Foetal growth restriction 62.85 10.36 44 35704 3541 29913189
Dysplastic naevus 61.11 10.36 21 35727 339 29916391
Drug abuse 60.86 10.36 12 35736 82060 29834670
Hypertension 60.73 10.36 296 35452 121058 29795672
Gingival hypertrophy 56.73 10.36 31 35717 1602 29915128
Cerebral infarction 50.66 10.36 103 35645 26270 29890460
Hyperkalaemia 45.19 10.36 177 35571 65833 29850897
Bezoar 45.07 10.36 22 35726 897 29915833
Polydactyly 44.44 10.36 24 35724 1211 29915519
Renal impairment 41.10 10.36 204 35544 83980 29832750
Off label use 40.44 10.36 157 35591 249133 29667597
Drug ineffective 39.79 10.36 241 35507 340146 29576584
Blood creatinine increased 37.46 10.36 211 35537 91164 29825566
Blood urea increased 36.71 10.36 101 35647 31280 29885450
Shock 36.67 10.36 83 35665 22776 29893954
Kidney transplant rejection 36.60 10.36 45 35703 7464 29909266
Oesophageal obstruction 36.35 10.36 15 35733 409 29916321
Death 33.37 10.36 270 35478 357013 29559717
Cardiac failure congestive 33.34 10.36 193 35555 84214 29832516
Protein urine present 32.44 10.36 34 35714 4741 29911989
Phospholipidosis 30.35 10.36 8 35740 48 29916682
Foetal exposure timing unspecified 25.94 10.36 10 35738 227 29916503
Completed suicide 25.79 10.36 205 35543 99287 29817443
Hypotonic-hyporesponsive episode 25.62 10.36 6 35742 20 29916710
Neutropenia 25.55 10.36 74 35674 128466 29788264
Incision site pain 24.87 10.36 20 35728 1984 29914746
Chronic kidney disease 24.70 10.36 100 35648 37738 29878992
Aplasia pure red cell 24.69 10.36 32 35716 5594 29911136
Pyelocaliectasis 23.93 10.36 15 35733 1002 29915728
Thrombotic cerebral infarction 23.50 10.36 10 35738 295 29916435
Blood pressure increased 23.10 10.36 156 35592 71772 29844958
Haemodilution 22.90 10.36 6 35742 35 29916695
Metabolic acidosis 22.88 10.36 97 35651 37364 29879366
Hypotension 22.13 10.36 349 35399 200216 29716514
Lymphocyte count decreased 21.95 10.36 61 35687 18994 29897736
Actinic keratosis 21.57 10.36 24 35724 3579 29913151
Hydrops foetalis 21.29 10.36 9 35739 261 29916469
HIV associated nephropathy 21.26 10.36 9 35739 262 29916468
Malignant hypertension 20.64 10.36 12 35736 699 29916031
Anti-erythropoietin antibody positive 20.58 10.36 13 35735 880 29915850
Pulmonary hypertension 20.04 10.36 59 35689 18977 29897753
Atrioventricular block complete 19.82 10.36 36 35712 8441 29908289
Procedural hypertension 19.56 10.36 6 35742 66 29916664
Cardiac arrest 19.18 10.36 182 35566 92668 29824062
Congenital cystic lung 19.02 10.36 8 35740 229 29916501
Proteinuria 18.91 10.36 52 35696 16093 29900637
Hepatic function abnormal 18.60 10.36 99 35649 41846 29874884
Blindness 17.88 10.36 43 35705 12266 29904464
Acute kidney injury 17.84 10.36 440 35308 273402 29643328
Fatigue 17.66 10.36 273 35475 320400 29596330
Renal failure 17.61 10.36 233 35515 128733 29787997
Lacunar infarction 17.17 10.36 20 35728 3135 29913595
Mixed connective tissue disease 17.01 10.36 5 35743 47 29916683
Blood pressure decreased 16.88 10.36 105 35643 46970 29869760
Agitation 16.82 10.36 24 35724 54049 29862681
Rickets 16.56 10.36 5 35743 52 29916678
Mucosal inflammation 16.29 10.36 8 35740 30486 29886244
Pulmonary eosinophilia 16.25 10.36 7 35741 213 29916517
Drug dependence 16.01 10.36 3 35745 21292 29895438
Caesarean section 15.93 10.36 16 35732 2121 29914609
Treatment failure 15.83 10.36 11 35737 34668 29882062
Acute lung injury 15.80 10.36 12 35736 1095 29915635
Red blood cells urine positive 15.67 10.36 14 35734 1603 29915127
Polyhydramnios 15.58 10.36 7 35741 236 29916494
Oedema 15.48 10.36 96 35652 42897 29873833
Patent ductus arteriosus 15.45 10.36 19 35729 3150 29913580
Renal ischaemia 15.30 10.36 9 35739 536 29916194
Rheumatoid arthritis 15.22 10.36 16 35732 41181 29875549
Pituitary tumour recurrent 15.20 10.36 5 35743 70 29916660
Sclerodactylia 15.17 10.36 4 35744 24 29916706
Bradycardia foetal 15.15 10.36 7 35741 252 29916478
Naevus flammeus 15.10 10.36 6 35742 148 29916582
Oesophageal haemorrhage 15.05 10.36 12 35736 1176 29915554
Febrile neutropenia 14.91 10.36 71 35677 106622 29810108
Hyphaema 14.88 10.36 8 35740 400 29916330
Drug level increased 14.87 10.36 52 35696 18302 29898428
Meningitis staphylococcal 14.83 10.36 5 35743 76 29916654
Congenital pulmonary valve atresia 14.71 10.36 5 35743 78 29916652
Drug interaction 14.61 10.36 326 35422 199242 29717488
Renal failure neonatal 14.53 10.36 5 35743 81 29916649
Neonatal cholestasis 14.52 10.36 4 35744 29 29916701
Cerebral hyperperfusion syndrome 14.42 10.36 5 35743 83 29916647
Post procedural urine leak 14.39 10.36 6 35742 168 29916562
Anti-neutrophil cytoplasmic antibody positive vasculitis 14.19 10.36 9 35739 614 29916116
Azotaemia 14.17 10.36 23 35725 4929 29911801
Aortic dissection 14.16 10.36 16 35732 2426 29914304
Diabetes mellitus 14.15 10.36 92 35656 41773 29874957
Hypertensive crisis 14.13 10.36 31 35717 8326 29908404
Maternal exposure during pregnancy 13.93 10.36 20 35728 3851 29912879
Neonatal respiratory distress 13.85 10.36 8 35740 460 29916270
Cerebrovascular accident 13.62 10.36 156 35592 83321 29833409
Blood pressure systolic 13.59 10.36 3 35745 7 29916723
Neonatal respiratory failure 13.56 10.36 7 35741 322 29916408
Blood pressure inadequately controlled 13.50 10.36 16 35732 2554 29914176
Infantile apnoea 13.50 10.36 10 35738 879 29915851
Nephrogenic systemic fibrosis 13.47 10.36 21 35727 4350 29912380
Palatal swelling 13.39 10.36 4 35744 40 29916690
Congenital musculoskeletal anomaly 13.14 10.36 6 35742 210 29916520
Hepatocellular injury 13.13 10.36 7 35741 25464 29891266
Myocardial ischaemia 13.12 10.36 48 35700 17269 29899461
Prinzmetal angina 13.10 10.36 10 35738 919 29915811
Exposure during pregnancy 13.08 10.36 32 35716 9229 29907501
Cardiac cirrhosis 13.04 10.36 4 35744 44 29916686
Product residue present 12.97 10.36 16 35732 2662 29914068
Chorioretinopathy 12.96 10.36 12 35736 1440 29915290
Neutrophil count increased 12.93 10.36 44 35704 15279 29901451
Product use in unapproved indication 12.82 10.36 45 35703 73648 29843082
Supernumerary nipple 12.80 10.36 4 35744 47 29916683
Wrong technique in product usage process 12.80 10.36 11 35737 31144 29885586
Ventricular septal defect 12.36 10.36 18 35730 3511 29913219
Haemoglobin decreased 12.35 10.36 198 35550 113900 29802830
Cardiac murmur 12.30 10.36 26 35722 6808 29909922
Nausea 12.19 10.36 266 35482 296691 29620039
Peripheral arterial occlusive disease 12.15 10.36 22 35726 5146 29911584
Transplant rejection 12.15 10.36 31 35717 9175 29907555
Pulmonary oedema 12.14 10.36 92 35656 43883 29872847
Myocardial infarction 12.13 10.36 214 35534 125411 29791319
Skin hypertrophy 12.07 10.36 15 35733 2514 29914216
Brain stem infarction 12.05 10.36 11 35737 1295 29915435
Neonatal respiratory distress syndrome 11.98 10.36 19 35729 3993 29912737
Angina pectoris 11.96 10.36 68 35680 29450 29887280
Interstitial lung disease 11.93 10.36 117 35631 60080 29856650
Renal cyst haemorrhage 11.89 10.36 5 35743 143 29916587
Systemic scleroderma 11.89 10.36 6 35742 263 29916467
Hypertensive emergency 11.72 10.36 9 35739 835 29915895
Therapeutic product effect incomplete 11.56 10.36 14 35734 33820 29882910
Gastric cancer 11.54 10.36 21 35727 4929 29911801
Adrenal adenoma 11.50 10.36 6 35742 282 29916448
Apnoeic attack 11.48 10.36 6 35742 283 29916447
Vertebral artery stenosis 11.40 10.36 5 35743 159 29916571
Pseudoaldosteronism 11.38 10.36 3 35745 18 29916712
Renal disorder 11.38 10.36 57 35691 23527 29893203
Anaemia neonatal 11.35 10.36 6 35742 290 29916440
Chronic allograft nephropathy 11.11 10.36 10 35738 1156 29915574
Maternal drugs affecting foetus 11.09 10.36 19 35729 4254 29912476
Delayed graft function 11.08 10.36 12 35736 1737 29914993
Bradycardia neonatal 11.07 10.36 9 35739 907 29915823
Altered state of consciousness 10.96 10.36 50 35698 19869 29896861
Diverticulum intestinal haemorrhagic 10.93 10.36 13 35735 2082 29914648
Vomiting 10.80 10.36 191 35557 219627 29697103
Thrombocytopenia 10.78 10.36 108 35640 136936 29779794
Myocardial fibrosis 10.70 10.36 8 35740 713 29916017
Ventricular extrasystoles 10.62 10.36 34 35714 11440 29905290
Bronchopulmonary dysplasia 10.55 10.36 7 35741 516 29916214
Cerebrovascular insufficiency 10.53 10.36 3 35745 25 29916705

Pharmacologic Action:

SourceCodeDescription
ATC C07FB03 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS, OTHER COMBINATIONS
Beta blocking agents and calcium channel blockers
ATC C08CA05 CARDIOVASCULAR SYSTEM
CALCIUM CHANNEL BLOCKERS
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
Dihydropyridine derivatives
ATC C08CA55 CARDIOVASCULAR SYSTEM
CALCIUM CHANNEL BLOCKERS
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
Dihydropyridine derivatives
ATC C08GA01 CARDIOVASCULAR SYSTEM
CALCIUM CHANNEL BLOCKERS
CALCIUM CHANNEL BLOCKERS AND DIURETICS
Calcium channel blockers and diuretics
FDA CS M0006414 Dihydropyridines
FDA MoA N0000000069 Calcium Channel Antagonists
FDA EPC N0000175421 Dihydropyridine Calcium Channel Blocker
MeSH PA D002121 Calcium Channel Blockers
MeSH PA D000077264 Calcium-Regulating Hormones and Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D012102 Reproductive Control Agents
MeSH PA D015149 Tocolytic Agents
MeSH PA D014665 Vasodilator Agents
CHEBI has role CHEBI:35620 vasodilator
CHEBI has role CHEBI:38215 calcium channel blockers
CHEBI has role CHEBI:66993 anti-contraction drug
CHEBI has role CHEBI:77746 h. sapiens metabolites

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Prinzmetal angina indication 87343002
Angina pectoris indication 194828000
Premature labor off-label use 6383007
Raynaud's phenomenon off-label use 266261006
Cirrhosis of liver contraindication 19943007 DOID:5082
Myocardial infarction contraindication 22298006 DOID:5844
Stenosis of intestine contraindication 23065003
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Chronic idiopathic constipation contraindication 82934008
Left heart failure contraindication 85232009
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Gastrointestinal obstruction contraindication 126765001
Disease of liver contraindication 235856003 DOID:409
Pyloric obstruction contraindication 244815007
Peripheral edema contraindication 271809000
Continent ileostomy - stoma contraindication 311414006
Non-Q wave myocardial infarction contraindication 314207007
Acute coronary syndrome contraindication 394659003
Porphyria contraindication 418470004
Severe Aortic Valve Stenosis contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.5 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel BLOCKER Kd 9.40 CHEMBL SCIENTIFIC LITERATURE
Voltage-dependent L-type calcium channel subunit alpha-1D Ion channel GATING INHIBITOR IC50 7.70 IUPHAR CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1F Ion channel GATING INHIBITOR IC50 6 IUPHAR
5-hydroxytryptamine receptor 2C GPCR Ki 5.02 DRUG MATRIX
Adenosine receptor A1 GPCR Ki 5.35 DRUG MATRIX
Cytochrome P450 1A2 Enzyme IC50 6.52 DRUG MATRIX
cAMP-specific 3',5'-cyclic phosphodiesterase 4A Enzyme IC50 4.35 DRUG MATRIX
Thromboxane-A synthase Enzyme IC50 4.73 DRUG MATRIX
C-C chemokine receptor type 2 GPCR Ki 6.07 DRUG MATRIX
Sodium/nucleoside cotransporter 1 Transporter Ki 5.09 DRUG MATRIX
Potassium voltage-gated channel subfamily A member 2 Ion channel Kd 4.70 WOMBAT-PK
Voltage-dependent T-type calcium channel subunit alpha-1H Ion channel Ki 4.67 WOMBAT-PK
Transthyretin Secreted IC50 5.66 WOMBAT-PK
Glycine receptor subunit alpha-1 Ion channel IC50 5.48 CHEMBL
Adenosine receptor A3 GPCR Ki 5.08 CHEMBL
Glutathione reductase, mitochondrial Enzyme Ki 4.76 CHEMBL
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 4.43 CHEMBL
Potassium voltage-gated channel subfamily A member 5 Ion channel IC50 5.21 CHEMBL
Adenosine receptor A2a GPCR Ki 4.65 CHEMBL
Cytochrome P450 3A4 Enzyme IC50 5.26 WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 4.30 WOMBAT-PK
Glycine receptor subunit alpha-3 Ion channel ANTAGONIST IC50 4.50 IUPHAR
Glycine receptor subunit beta Ion channel ANTAGONIST IC50 5.90 IUPHAR
Bile salt export pump Transporter IC50 4.51 CHEMBL
Myosin light chain kinase, smooth muscle Kinase IC50 5.69 CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1S Ion channel INHIBITOR IC50 6.30 IUPHAR
5-hydroxytryptamine receptor 2A GPCR Ki 6.49 PDSP
Arachidonate 15-lipoxygenase Enzyme IC50 4.82 DRUG MATRIX
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel IC50 9 CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel IC50 8.59 CHEMBL
Adenosine receptor A2a GPCR Ki 4.74 CHEMBL
Cholinesterase Enzyme Ki 5.92 CHEMBL
Voltage-gated L-type calcium channel Ion channel Ki 8.33 CHEMBL
Adenosine receptor A1 GPCR Ki 5.54 CHEMBL
Indoleamine 2,3-dioxygenase 1 Enzyme IC50 4.34 CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1D Ion channel Ki 8.92 CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel Ki 8.46 CHEMBL
Acetylcholinesterase Enzyme Ki 5.40 CHEMBL
Indoleamine 2,3-dioxygenase 2 Enzyme IC50 5.82 CHEMBL
Bile salt export pump Unclassified IC50 4.34 CHEMBL
Potassium voltage-gated channel subfamily A member 1 Unclassified BLOCKER IC50 4 IUPHAR
Potassium voltage-gated channel subfamily A member 2 Unclassified BLOCKER Kd 4.70 IUPHAR
Potassium voltage-gated channel subfamily A member 7 Unclassified BLOCKER IC50 4.90 IUPHAR

External reference:

IDSource
4018390 VUID
N0000146717 NUI
D00437 KEGG_DRUG
4018390 VANDF
C0028066 UMLSCUI
CHEBI:7565 CHEBI
C5U PDB_CHEM_ID
CHEMBL193 ChEMBL_ID
D009543 MESH_DESCRIPTOR_UI
DB01115 DRUGBANK_ID
2514 IUPHAR_LIGAND_ID
3222 INN_ID
I9ZF7L6G2L UNII
4485 PUBCHEM_CID
7417 RXNORM
2302 MMSL
5175 MMSL
d00051 MMSL
000710 NDDF
017700 NDDF
387490003 SNOMEDCT_US
85272000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Procardia HUMAN PRESCRIPTION DRUG LABEL 1 0069-2600 CAPSULE 10 mg ORAL NDA 20 sections
Procardia XL HUMAN PRESCRIPTION DRUG LABEL 1 0069-2650 TABLET, FILM COATED, EXTENDED RELEASE 30 mg ORAL NDA 20 sections
Procardia XL HUMAN PRESCRIPTION DRUG LABEL 1 0069-2660 TABLET, FILM COATED, EXTENDED RELEASE 60 mg ORAL NDA 20 sections
Procardia XL HUMAN PRESCRIPTION DRUG LABEL 1 0069-2670 TABLET, FILM COATED, EXTENDED RELEASE 90 mg ORAL NDA 20 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 0228-2497 CAPSULE, LIQUID FILLED 10 mg ORAL ANDA 19 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 0228-2530 CAPSULE, LIQUID FILLED 20 mg ORAL ANDA 19 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 0904-7080 TABLET, EXTENDED RELEASE 30 mg ORAL ANDA 19 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 0904-7081 TABLET, EXTENDED RELEASE 60 mg ORAL ANDA 19 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 0904-7082 TABLET, EXTENDED RELEASE 90 mg ORAL ANDA 19 sections
NIFEDIPINE HUMAN PRESCRIPTION DRUG LABEL 1 16590-319 CAPSULE, LIQUID FILLED 10 mg ORAL ANDA 19 sections
NIFEDIPINE HUMAN PRESCRIPTION DRUG LABEL 1 16590-948 TABLET, FILM COATED, EXTENDED RELEASE 60 mg ORAL ANDA 11 sections
nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 21695-807 TABLET, FILM COATED, EXTENDED RELEASE 90 mg ORAL ANDA 20 sections
nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 21695-908 TABLET, FILM COATED, EXTENDED RELEASE 30 mg ORAL ANDA 20 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 21695-909 TABLET, EXTENDED RELEASE 60 mg ORAL ANDA 14 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 23155-194 CAPSULE 10 mg ORAL ANDA 19 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 23155-195 CAPSULE 20 mg ORAL ANDA 19 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 24979-009 TABLET, EXTENDED RELEASE 90 mg ORAL ANDA 11 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 24979-009 TABLET, EXTENDED RELEASE 90 mg ORAL ANDA 11 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 24979-010 TABLET, EXTENDED RELEASE 60 mg ORAL ANDA 11 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 24979-010 TABLET, EXTENDED RELEASE 60 mg ORAL ANDA 11 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 24979-011 TABLET, EXTENDED RELEASE 30 mg ORAL ANDA 11 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 24979-011 TABLET, EXTENDED RELEASE 30 mg ORAL ANDA 11 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 33261-840 TABLET, FILM COATED, EXTENDED RELEASE 90 mg ORAL ANDA 22 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 42192-615 CAPSULE, LIQUID FILLED 10 mg ORAL ANDA 17 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 42254-095 TABLET, FILM COATED, EXTENDED RELEASE 60 mg ORAL ANDA 22 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 43353-209 TABLET, EXTENDED RELEASE 60 mg ORAL ANDA 25 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 43353-750 TABLET, FILM COATED, EXTENDED RELEASE 90 mg ORAL ANDA 22 sections
AfeditabCR HUMAN PRESCRIPTION DRUG LABEL 1 43353-782 TABLET, FILM COATED, EXTENDED RELEASE 60 mg ORAL ANDA 13 sections
AfeditabCR HUMAN PRESCRIPTION DRUG LABEL 1 43353-792 TABLET, FILM COATED, EXTENDED RELEASE 30 mg ORAL ANDA 13 sections
Nifedipine HUMAN PRESCRIPTION DRUG LABEL 1 43353-836 TABLET, FILM COATED, EXTENDED RELEASE 60 mg ORAL ANDA 22 sections